Bausch + Lomb Co. (NYSE:BLCO) Shares Sold by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP lowered its holdings in shares of Bausch + Lomb Co. (NYSE:BLCO) by 60.3% in the fourth quarter, Holdings Channel reports. The firm owned 366,721 shares of the company’s stock after selling 557,760 shares during the quarter. ExodusPoint Capital Management LP’s holdings in Bausch + Lomb were worth $6,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of BLCO. Blue Trust Inc. grew its stake in shares of Bausch + Lomb by 68.3% in the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock valued at $48,000 after purchasing an additional 1,004 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Bausch + Lomb during the fourth quarter worth $72,000. Commonwealth Equity Services LLC purchased a new position in Bausch + Lomb in the 4th quarter valued at $181,000. Orion Portfolio Solutions LLC acquired a new position in Bausch + Lomb in the 4th quarter valued at $225,000. Finally, Gordian Capital Singapore Pte Ltd purchased a new position in Bausch + Lomb during the 3rd quarter worth $289,000. 11.07% of the stock is owned by hedge funds and other institutional investors.

Bausch + Lomb Trading Down 7.2 %

Shares of BLCO stock opened at $12.05 on Friday. The stock has a market cap of $4.25 billion, a P/E ratio of -13.24, a P/E/G ratio of 0.85 and a beta of 0.54. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72. Bausch + Lomb Co. has a fifty-two week low of $11.94 and a fifty-two week high of $21.69. The business has a fifty day simple moving average of $15.88 and a 200-day simple moving average of $17.98.

Bausch + Lomb (NYSE:BLCO) last posted its earnings results on Wednesday, February 19th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.02. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The firm had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period last year, the firm posted $0.24 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. On average, analysts forecast that Bausch + Lomb Co. will post 0.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Citigroup downgraded shares of Bausch + Lomb from a “buy” rating to a “neutral” rating and lowered their target price for the company from $24.00 to $22.00 in a report on Wednesday, December 11th. Wells Fargo & Company reiterated an “equal weight” rating and set a $15.00 target price (down previously from $24.00) on shares of Bausch + Lomb in a research report on Friday, March 28th. Stifel Nicolaus cut their target price on Bausch + Lomb from $17.00 to $15.00 and set a “hold” rating for the company in a research note on Thursday. Needham & Company LLC reaffirmed a “hold” rating on shares of Bausch + Lomb in a report on Thursday, February 20th. Finally, Royal Bank of Canada cut their price objective on Bausch + Lomb from $18.00 to $17.00 and set an “outperform” rating for the company in a research report on Friday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Bausch + Lomb has an average rating of “Hold” and a consensus target price of $18.82.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.